{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:53:09Z","timestamp":1785851589384,"version":"3.56.0"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007155","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/W006804\/1"],"award-info":[{"award-number":["MR\/W006804\/1"]}],"id":[{"id":"10.13039\/501100007155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>5\u03b1-Reductase inhibitors are prescribed for the treatment of benign prostatic hyperplasia (BPH) and their use is associated with increased risk of incident type 2 diabetes. This study assessed the long-term cardiovascular safety of 5\u03b1-reductase inhibitors in comparison with tamsulosin in people with co-existing BPH and type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We performed a retrospective, population-based cohort study using Scottish Diabetes Research Network National Diabetes Dataset (SDRN-NDS) and IQVIA Medical Research Data (IMRD-UK). BPH patients \u226540 years with recorded type 2 diabetes mellitus and \u22652 prescriptions of 5\u03b1-reductase inhibitors or tamsulosin (2006\u20132021) were included. After 1:2 variable ratio propensity score matching, cause-specific Cox proportional-hazard models were used to compute the hazard ratio (HR) of incident major adverse cardiovascular events (MACE). A total of 11 969 patients were included in SDRN-NDS and 16 492 in IMRD-UK, with median follow-up durations of 3.8 (IQR: 1.7\u20136.8) and 4.8 (2.0\u20138.3) years, respectively. In SDRN-NDS, the HR of MACE in patients receiving 5\u03b1-reductase inhibitors relative to tamsulosin was 1.15 (95% CI 1.03\u20131.30, P = 0.007), driven by increased risk of myocardial infarction (MI) (HR 1.20, 1.03\u20131.40, P = 0.022). This was replicated in IMRD-UK, where HR was 1.26 (1.07\u20131.47, P = 0.008) for MACE and 1.33 (1.10\u20131.60, P = 0.005) for MI. We did not observe any increased risks in stroke, cardiovascular death, microvascular complications of diabetes, or faster progression to insulin-based therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our retrospective data from two large cohorts suggest that the risk of MACE may be increased among patients with type 2 diabetes taking 5\u03b1-reductase inhibitors, potentially driven by increased risk of MI. This supports careful monitoring of macrovascular outcomes when prescribing 5\u03b1-reductase inhibitors in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvag003","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T12:46:53Z","timestamp":1768394813000},"page":"97-107","source":"Crossref","is-referenced-by-count":2,"title":["Cardiovascular safety of 5\u03b1-reductase inhibitors in people with benign prostatic hyperplasia and type 2 diabetes: a propensity score-matched analysis"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4828-6314","authenticated-orcid":false,"given":"Haolan","family":"Tu","sequence":"first","affiliation":[{"name":"Institute for Neuroscience and Cardiovascular Research, University of Edinburgh , 47 Little France Crescent, Edinburgh EH16 4TJ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7860-6262","authenticated-orcid":false,"given":"Chengsheng","family":"Ju","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University College London , London WC1H 9EU ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart J","family":"McGurnaghan","sequence":"additional","affiliation":[{"name":"MRC Unit for Human Genetics, University of Edinburgh , Edinburgh EH4 2XU ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke A K","family":"Blackbourn","sequence":"additional","affiliation":[{"name":"MRC Unit for Human Genetics, University of Edinburgh , Edinburgh EH4 2XU ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Scottish Diabetes Research Network Epidemiology Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hanlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"McAllister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Petrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Kennon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Philip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewan","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Berthon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Blackbourn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Colhoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"McGurnaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"McKeigue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Wild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9237-8585","authenticated-orcid":false,"given":"Ewan","family":"Pearson","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Dundee , Dundee DD1 9SY ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8840-7267","authenticated-orcid":false,"given":"Li","family":"Wei","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University College London , London WC1H 9EU ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6916-2994","authenticated-orcid":false,"given":"Ruth","family":"Andrew","sequence":"additional","affiliation":[{"name":"Institute for Neuroscience and Cardiovascular Research, University of Edinburgh , 47 Little France Crescent, Edinburgh EH16 4TJ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,17]]},"reference":[{"key":"2026022706313839200_pvag003-B1","author":"National Institute for Health and Care Excellence","year":"2015"},{"key":"2026022706313839200_pvag003-B2","doi-asserted-by":"publisher","first-page":"E1397","DOI":"10.1210\/jc.2014-1395","article-title":"5\u03b1-reductase type 1 modulates insulin sensitivity in men","volume":"99","author":"Upreti","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2026022706313839200_pvag003-B3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1210\/jc.2015-2928","article-title":"Dual-5\u03b1-reductase inhibition promotes hepatic lipid accumulation in man","volume":"101","author":"Hazlehurst","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2026022706313839200_pvag003-B4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1515\/hmbci-2017-0015","article-title":"Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction","volume":"30","author":"Traish","year":"2017","journal-title":"Horm Mol Biol Clin Investig"},{"key":"2026022706313839200_pvag003-B5","doi-asserted-by":"publisher","first-page":"l1204","DOI":"10.1136\/bmj.l1204","article-title":"Incidence of type 2 diabetes mellitus in men receiving steroid 5\u03b1-reductase inhibitors: population based cohort study","volume":"365","author":"Wei","year":"2019","journal-title":"BMJ"},{"key":"2026022706313839200_pvag003-B6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1530\/joe-16-0125","article-title":"Metabolic dysfunction in female mice with disruption of 5\u03b1-reductase 1","volume":"232","author":"Livingstone","year":"2017","journal-title":"J Endocrinol"},{"key":"2026022706313839200_pvag003-B7","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1210\/en.2019-00236","article-title":"Role of hepatic glucocorticoid receptor in metabolism in models of 5\u03b1R1 deficiency in male mice","volume":"160","author":"Mak","year":"2019","journal-title":"Endocrinology"},{"key":"2026022706313839200_pvag003-B8","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.1210\/en.2013-1592","article-title":"Loss of 5\u03b1-reductase type 1 accelerates the development of hepatic steatosis but protects against hepatocellular carcinoma in male mice","volume":"154","author":"Dowman","year":"2013","journal-title":"Endocrinology"},{"key":"2026022706313839200_pvag003-B9","doi-asserted-by":"publisher","first-page":"447","DOI":"10.2337\/db14-0249","article-title":"5\u03b1-Reductase type 1 deficiency or inhibition predisposes to Insulin resistance, hepatic steatosis, and liver fibrosis in rodents","volume":"64","author":"Livingstone","year":"2015","journal-title":"Diabetes"},{"key":"2026022706313839200_pvag003-B10","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(14)70219-0","article-title":"Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1\u00b7 9 million people","volume":"3","author":"Shah","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026022706313839200_pvag003-B11","doi-asserted-by":"publisher","first-page":"e063046","DOI":"10.1136\/bmjopen-2022-063046","article-title":"Cohort profile: the Scottish Diabetes Research Network national diabetes cohort\u2014a population-based cohort of people with diabetes in Scotland","volume":"12","author":"McGurnaghan","year":"2022","journal-title":"BMJ Open"},{"key":"2026022706313839200_pvag003-B12","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/978-3-030-51455-6_4","volume-title":"Databases Pharmacoepidemiol Res","author":"Myland","year":"2021"},{"key":"2026022706313839200_pvag003-B13","doi-asserted-by":"publisher","first-page":"251","DOI":"10.14236\/jhi.v19i4.820","article-title":"Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates","volume":"19","author":"Blak","year":"2011","journal-title":"Inform Prim Care"},{"key":"2026022706313839200_pvag003-B14","author":"Scottish Government","year":"2020"},{"key":"2026022706313839200_pvag003-B15","doi-asserted-by":"publisher","first-page":"e078483","DOI":"10.1136\/bmj-2023-078483","article-title":"SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study","volume":"385","author":"Fu","year":"2024","journal-title":"BMJ"},{"key":"2026022706313839200_pvag003-B16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1017\/S0047279400020341","article-title":"Deprivation","volume":"16","author":"Townsend","year":"1987","journal-title":"J Soc Policy"},{"key":"2026022706313839200_pvag003-B17","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/j.0006-341X.2000.00118.x","article-title":"Substantial gains in bias reduction from matching with a variable number of controls","volume":"56","author":"Ming","year":"2000","journal-title":"Biometrics"},{"key":"2026022706313839200_pvag003-B18","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1136\/heartjnl-2020-317870","article-title":"Monitoring indirect impact of COVID-19 pandemic on services for cardiovascular diseases in the UK","volume":"106","author":"Ball","year":"2020","journal-title":"Heart"},{"key":"2026022706313839200_pvag003-B19","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/ncpuro0836","article-title":"Pharmacology of \u03b11-adrenoceptor antagonists in the lower urinary tract and central nervous system","volume":"4","author":"Andersson","year":"2007","journal-title":"Nat Clin Pract Urol"},{"key":"2026022706313839200_pvag003-B20","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/(SICI)1097-0045(19970215)30:3<202::AID-PROS9>3.0.CO;2-N","article-title":"Prostatic \u03b11-adrenoceptors and uroselectivity","volume":"30","author":"Andersson","year":"1997","journal-title":"Prostate"},{"key":"2026022706313839200_pvag003-B21","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2165\/00002512-200219020-00004","article-title":"Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms","volume":"19","author":"Dunn","year":"2002","journal-title":"Drugs Aging"},{"key":"2026022706313839200_pvag003-B22","first-page":"155","article-title":"Tamsulosin, the first prostate-selective \u03b1 (1A)-adrenoceptor antagonist","volume":"29","author":"Chapple","year":"1996","journal-title":"Eur Urol"},{"key":"2026022706313839200_pvag003-B23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000052284","article-title":"Cardiovascular effects of alpha-blockers used for the treatment of symptomatic BPH: impact on safety and well-being","volume":"34","author":"de Mey","year":"1998","journal-title":"Eur Urol"},{"key":"2026022706313839200_pvag003-B24","author":"National Institute for Health and Care Excellence","year":"2019"},{"key":"2026022706313839200_pvag003-B25","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1007\/s00125-018-4796-7","article-title":"Trends in incidence and case fatality of acute myocardial infarction, angina and coronary revascularisation in people with and without type 2 diabetes in Scotland between 2006 and 2015","volume":"62","author":"Read","year":"2019","journal-title":"Diabetologia"},{"key":"2026022706313839200_pvag003-B26","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1177\/2047487317736824","article-title":"Cardiovascular outcomes for patients with symptomatic peripheral artery disease: a cohort study in The Health Improvement Network (THIN) in the UK","volume":"24","author":"Cea Soriano","year":"2017","journal-title":"Eur J Prev Cardiol"},{"key":"2026022706313839200_pvag003-B27","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1056\/NEJMoa0908127","article-title":"Effect of dutasteride on the risk of prostate cancer","volume":"362","author":"Andriole Gerald","year":"2010","journal-title":"N Engl J Med"},{"key":"2026022706313839200_pvag003-B28","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/jcpt.12080","article-title":"Systematic review evaluating cardiovascular events of the 5-alpha reductase inhibitor\u2014dutasteride","volume":"38","author":"Loke","year":"2013","journal-title":"J Clin Pharm Ther"},{"key":"2026022706313839200_pvag003-B29","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.amjmed.2023.06.021","article-title":"The cardiovascular safety of five-alpha-reductase inhibitors among men with benign prostatic hyperplasia: a population-based cohort study","volume":"136","author":"Ayele","year":"2023","journal-title":"Am J Med"},{"key":"2026022706313839200_pvag003-B30","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1097\/JU.0000000000001561","article-title":"Cardiac failure associated with medical therapy of benign prostatic hyperplasia: a population based study","volume":"205","author":"Lusty","year":"2021","journal-title":"J Urol"},{"key":"2026022706313839200_pvag003-B31","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/aje\/kwr301","article-title":"Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins","volume":"175","author":"Danaei","year":"2012","journal-title":"Am J Epidemiol"},{"key":"2026022706313839200_pvag003-B32","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3390\/jcm8050733","article-title":"Cardiovascular safety and possible benefit of a 5-alpha reductase inhibitor among benign prostatic hyperplasia patients, a nationally representative cohort of Korean men","volume":"8","author":"Chang","year":"2019","journal-title":"J Clin Med"},{"key":"2026022706313839200_pvag003-B33","doi-asserted-by":"publisher","first-page":"e2343299","DOI":"10.1001\/jamanetworkopen.2023.43299","article-title":"Cardiovascular outcomes of \u03b1-blockers vs 5-\u03b1 reductase inhibitors for benign prostatic hyperplasia","volume":"6","author":"Zhang","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026022706313839200_pvag003-B34","doi-asserted-by":"crossref","first-page":"e0119694","DOI":"10.1371\/journal.pone.0119694","article-title":"Use of 5-alpha-reductase inhibitors did not increase the risk of cardiovascular diseases in patients with benign prostate hyperplasia: a five-year follow-up study","volume":"10","author":"Hsieh","year":"2015","journal-title":"PLoS One"},{"key":"2026022706313839200_pvag003-B35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1161\/01.STR.24.1.35","article-title":"Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment","volume":"24","author":"Adams","year":"1993","journal-title":"Stroke"},{"key":"2026022706313839200_pvag003-B36","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/eurheartj\/eht409","article-title":"Reperfusion therapy of acute ischaemic stroke and acute myocardial infarction: similarities and differences","volume":"35","author":"Widimsky","year":"2013","journal-title":"Eur Heart J"},{"key":"2026022706313839200_pvag003-B37","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1093\/eurheartj\/ehae371","article-title":"Acute myocardial infarction and ischaemic stroke: differences and similarities in reperfusion therapies\u2014a review","volume":"45","author":"Scheldeman","year":"2024","journal-title":"Eur Heart J"},{"key":"2026022706313839200_pvag003-B38","doi-asserted-by":"publisher","first-page":"e016947","DOI":"10.1161\/JAHA.120.016947","article-title":"Metabolic dyslipidemia and cardiovascular outcomes in type 2 diabetes mellitus: findings from the look AHEAD study","volume":"10","author":"Kaze","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026022706313839200_pvag003-B39","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1093\/eurheartj\/ehi407","article-title":"Plasma lipids predict myocardial infarction, but not stroke, in patients with established cerebrovascular disease","volume":"26","author":"Patel","year":"2005","journal-title":"Eur Heart J"},{"key":"2026022706313839200_pvag003-B40","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1530\/eje-07-0455","article-title":"Glucocorticoids and cardiovascular disease","volume":"157","author":"Walker","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"2026022706313839200_pvag003-B41","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1093\/ajh\/hpy120","article-title":"Mineralocorticoid receptor and cardiovascular disease","volume":"31","author":"Buonafine","year":"2018","journal-title":"Am J Hypertens"},{"key":"2026022706313839200_pvag003-B42","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1210\/er.2012-1008","article-title":"Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects","volume":"34","author":"Stanczyk","year":"2013","journal-title":"Endocr Rev"},{"key":"2026022706313839200_pvag003-B43","doi-asserted-by":"crossref","first-page":"e000272","DOI":"10.1161\/JAHA.113.000272","article-title":"Testosterone and the cardiovascular system: a comprehensive review of the clinical literature","volume":"2","author":"Oskui","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"2026022706313839200_pvag003-B44","doi-asserted-by":"publisher","first-page":"764","DOI":"10.7326\/0003-4819-141-10-200411160-00007","article-title":"Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease","volume":"141","author":"Wei","year":"2004","journal-title":"Ann Intern Med"},{"key":"2026022706313839200_pvag003-B45","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1530\/joe-13-0563","article-title":"Relative adrenal insufficiency in mice deficient in 5\u03b1-reductase 1","volume":"222","author":"Livingstone","year":"2014","journal-title":"J Endocrinol"},{"key":"2026022706313839200_pvag003-B46","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1111\/j.1476-5381.2011.01465.x","article-title":"5\u03b1-reduced glucocorticoids exhibit dissociated anti-inflammatory and metabolic effects","volume":"164","author":"Yang","year":"2011","journal-title":"Br J Pharmacol"},{"key":"2026022706313839200_pvag003-B47","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.steroids.2014.05.010","article-title":"Adverse health effects of testosterone deficiency (TD) in men","volume":"88","author":"Traish","year":"2014","journal-title":"Steroids"},{"key":"2026022706313839200_pvag003-B48","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.mayocp.2014.10.011","article-title":"Testosterone therapy and cardiovascular risk: advances and controversies","volume":"90","author":"Morgentaler","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"2026022706313839200_pvag003-B49","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1530\/eje.1.02045","article-title":"Association of subclinical hypercortisolism with type 2 diabetes mellitus: a case-control study in hospitalized patients","volume":"153","author":"Chiodini","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"2026022706313839200_pvag003-B50","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2337\/dc06-1267","article-title":"Cortisol secretion in patients with type 2 diabetes: relationship with chronic complications","volume":"30","author":"Chiodini","year":"2007","journal-title":"Diabetes Care"},{"key":"2026022706313839200_pvag003-B51","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1001\/archpsyc.1983.01790220076012","article-title":"Abnormal results of dexamethasone suppression tests in nondepressed patients with diabetes mellitus","volume":"41","author":"Hudson","year":"1984","journal-title":"Arch Gen Psychiatry"},{"key":"2026022706313839200_pvag003-B52","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1210\/jc.2007-2177","article-title":"Low testosterone levels are common and associated with insulin resistance in men with diabetes","volume":"93","author":"Grossmann","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2026022706313839200_pvag003-B53","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/jdi.12288","article-title":"Testosterone level in men with type 2 diabetes mellitus and related metabolic effects: a review of current evidence","volume":"6","author":"Cheung","year":"2015","journal-title":"J Diabetes Investig"},{"key":"2026022706313839200_pvag003-B54","doi-asserted-by":"publisher","first-page":"5587","DOI":"10.1210\/jc.2002-020048","article-title":"Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance","volume":"87","author":"Andrews","year":"2002","journal-title":"J Clin Endocrinol Metab"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvag003\/66430870\/pvag003.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/12\/2\/97\/66430870\/pvag003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/12\/2\/97\/66430870\/pvag003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T11:31:49Z","timestamp":1772191909000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/12\/2\/97\/8427475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,17]]},"references-count":54,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1,17]]},"published-print":{"date-parts":[[2026,2,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvag003","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,17]]}}}